Join scPharmaceuticals for a KOL webinar focused on a nephrologist’s perspective on the use of FUROSCIX for treating fluid overload in heart failure and potential use in chronic kidney disease. Dr. Michael Aaronson, MD (Lincoln Nephrology and Hypertension, Lincoln, NE) will share his perspectives on how FUROSCIX can be part of a new treatment paradigm for edema due to fluid overload in patients with chronic kidney disease (CKD).

The FDA has assigned a PDUFA target action date of March 6, 2025, to consider scPharma’s Supplemental New Drug Application (sNDA) seeking to expand the FUROSCIX indication to include CKD.

scPharma management will also provide a corporate update focused on the company’s long-term growth initiatives, including the FDA-approved expansion of the FUROSCIX label to include NYHA Class IV heart failure patients, potential expansion of the FUROSCIX label to include CKD patients, and the ongoing development of a low-volume auto-injector designed to provide physicians and patients with additional FUROSCIX dosing flexibility.

A live question and answer session will follow the formal presentation.